

---

# Index

---

- abortion 28, 61, 66–7, 344, 484–5  
Abraham, J 164, 227  
abuse of dominant position 273–5,  
276, 277–8  
access to healthcare 295–300, 307,  
309–10, 311  
advanced therapy medicinal products  
(ATMPs) 25, 98, 159, 161, 212,  
214–17, 220–21, 224–6, 240  
hospital exemption 215, 217  
advertising  
alcohol 372, 374, 375, 377, 386,  
389–90, 395  
food 399, 408, 409, 417–18  
nutrition and health claims 414  
pharmaceuticals 168  
tobacco 27, 76, 351, 352, 354–5, 366,  
475, 492  
aflatoxins 430  
ageing, population 35, 126, 144, 300  
agencies and networks 43–4, 326–7,  
346  
health technology assessment  
network 310  
*see also individual agencies*  
Aginam, O 465  
agriculture 24, 316, 332, 333, 336, 342,  
408  
antibiotics as feed additives 420  
AIDS/HIV 107, 118, 134, 159, 227,  
316, 321, 340, 342–3, 459, 471, 474  
Akrich, M 140  
Akst, J 134  
alcohol 20, 59, 60–61, 68, 90, 356, 363,  
369–97, 455  
EU Alcohol Strategy 2006–2012 and  
Forum 383–6, 395–7  
EU judicial scrutiny 370  
international context 370–74  
national policies and internal  
market 374–80  
EU regulation of cross-border trade  
381–94  
mainstreaming public health  
382–91  
subsidiarity 391–4  
European Action Plan 371–3  
evidence-based action 371, 373, 379,  
380, 394, 395, 396, 397  
investment protection 449  
minimum prices 68–9, 372, 374, 376,  
378, 380  
public health as fundamental right  
106  
trade law 438  
Alemanno, A 18, 20, 317, 352, 354,  
363, 366, 369, 377, 378, 379, 380,  
394, 395, 400, 410, 412, 476  
Alexy, R 67, 483  
Alliance of Liberals and Democrats in  
Europe (ALDE) 48, 49, 56  
Alston, P 82, 485  
Altenstetter, C 26, 44, 198, 217  
Alter, KJ 72, 320  
Alwan, A 407  
Amaral, S 124  
Ancans, J 225  
Anderson, P 369, 373, 374, 395,  
396  
Andorno, R 342, 484  
Andrews, L 239  
Andriukaitis, V 400  
animals 207, 223, 316, 317, 318, 335,  
336, 340, 346  
antibiotics 398, 399, 404, 419–23,  
430, 447  
bovine spongiform encephalopathy  
(BSE) 24, 38, 40, 138, 233, 316,  
321, 323, 328, 333, 336, 340,  
342, 381, 398–9, 400  
unsafe feed 404  
Annas, GJ 315, 484  
anonymisation 262  
Anthrax 318, 322  
Anti-Counterfeiting Trade Agreement  
(ACTA) 434

- antimicrobial resistance (AMR) 399, 419–23, 430, 445
  - Transatlantic Taskforce on 447
- Apple's 'Health Kit' 244
- applicable law
  - eHealth 249–50
- arbitration
  - investment protection, ongoing legal uncertainty and 448–51
- Arena, A 439
- Armstrong, KA 80
- Arnstein, SR 139–40
- Arnulf, A 63, 80, 137
- Aschemann-Witzel, J 412
- Ashcroft, R 454
- Asif, J 185
- van Asselt, M 492
- austerity 111–12, 122, 132
  - Italy: foreign nurses 126–8
  - Portugal: EU law, health workforce and 123–5
  - see also* Eurozone crisis
- Australia 119, 449
- Austria 65–6, 119, 187, 309
- autonomy 237, 238, 240, 315, 365
- Avineri, S 63
- Azzopardi-Muscat, N 57, 58
  
- Babor, T 369, 449
- Bache, G 137, 200, 224, 226, 235, 468
- Bachrach, P 336
- Baeten, R 34, 46, 53, 113, 115, 117–18, 132, 133, 252, 295, 492
- Bagatur, S 480, 485
- Baker, BK 448
- Baldwin, R 138
- Barnard, C 27
- Bartels, L 463
- Bartl, H 176
- Bartlett, O 374, 380, 381, 385, 391, 397, 418
- Barton, AJ 255
- Bartsch, S 338
- Baumberg, B 374
- Beauchamp, TL 480
- Beck, U 142
- behavioural economics 365
- behavioural science 405–6, 413
- Beitz, CR 80
- Belgium 236, 287–8
  - ePrescriptions 252
  - health professional mobility 119, 124, 129
  - Patients' Rights Directive 49, 52
- Bell, D 142
- Bertinato, L 126, 127
- Besselink, LFM 487
- Beyers, J 40
- Bickerstaff, K 140
- Biehl, J 154, 471
- big health data 256
- Bijker, WE 143
- bilateral agreements 431
  - blood and blood components 233
  - counterfeit medicines 253
  - free trade agreements 373, 431–2, 438, 466, 469–70
  - EU-Caribbean 443
  - EU-Japan 435
  - EU-Korea 443, 472
  - EU-Singapore 438, 442
  - health professional mobility 127, 131
  - investment 449–50
- Biobanking and BioMolecular Resources Research Infrastructure (BBMRI-ERIC) 204
- biobanks 134, 146, 204, 231
  - consent 236–7
  - cord blood 238
- biodiversity schemes 148
- bioethics 480, 483–4, 493
- biological or chemical agents 323
- biomedical research law and policy 144
  - and citizen science 134–55, 495
  - electronic health records (EHRs) 261
  - funding 98, 146, 149–51, 155, 201–5, 220, 235, 491, 494
  - human materials 223, 240
  - consent 236–7
  - mHealth data 258
  - new health technologies *see separate entry*
- biomedical research law and policy and citizen science 134–55, 495
  - conceptualising 137–43
  - degrees of power 139–40, 141, 154
  - digital agenda 144–5
  - biomedical research, open science and 145–7

- harnessing and shaping citizen science
  - defining 148–9
  - enrolling citizens 153–4
  - funding 149–51
  - policy-based underpinnings 151–2
- key agendas for further work 154–5
- priorities, overarching 143–5, 149, 150, 152, 154
- promissory discourses 141, 154
- Biondi, A 374
- biopolitics 142
- biotechnologies 145, 197, 198–200, 227
  - cell therapy 198, 205
  - definition 198
  - gene therapy 198, 205, 213, 215, 494
  - marketing 211
    - medical devices 211, 215, 217–19, 220–21
    - medicinal products 159, 211–17, 220–21, 224–7
  - patents 88, 95–7, 205–10, 219–20, 235
  - research funding 201–5, 220, 235
- bioterrorism 318, 322, 325
- biovigilance 228
- Birnbaum, SL 173
- Black, J 135, 139, 349
- blood and blood components 103, 222, 227, 228–9, 230–31, 238–9, 241, 455
  - communicable diseases 316, 342–3
  - cross-border exchange 232–3
- Bogart, WA 347, 349, 350
- von Bogdandy, A 61, 82, 104, 485
- Bonadio, E 208
- Borg, J-J 306
- Borgmeier, I 411, 412
- Borup, M 153, 154
- Börzel, TA 86
- Botosaneanu, A 326
- bovine spongiform encephalopathy (BSE)/new variant Creutzfeld-Jacob Disease 24, 38, 40, 138, 233, 316, 321, 323, 328, 333, 336, 340, 342, 381, 398–9, 400
- Boyle, Danny 60
- Bozik, A 465
- Bradford, A 401
- Brandt, AM 350
- breast implants 218
- Broberg, M 463
- Brooks, E 21
- Brosset, E 199
- Brown, N 141
- Brown, W 143
- Brownson, RC 395
- Brownsword, R 138, 139, 140, 153, 454
- Buchan, J 111, 112, 118
- Bulgaria 56–7, 297
- Burgard, SA 342
- Burley, A-M 67, 71
- Burron, C 465
- Burute, N 245
- Busby, H 152
- Buse, K 457, 460
- Calo, ZR 88
- Campbell, C 395
- Campbell, J 111, 132
- Campos, A 125
- Canada 119
  - EU-Canada Comprehensive Economic and Trade Agreement (CETA) 435, 438, 440, 441–3, 449, 450–51, 467
  - trade disputes 429–30, 450
- cancer 38, 78, 159, 198, 215
- Capps, P 80
- cardiovascular diseases 198, 202, 405, 407
- Cardwell, PJ 466
- Carens, JH 339
- carers 117, 126
- Caribbean countries 437, 443, 466, 472
- Caro de Sousa, P 67
- cartels *see* competition law and policy
- Carter, P 141
- Casswell, S 396
- Castells, M 142
- Cazala, J 405
- CE mark 26, 178, 217, 218
  - mHealth 255, 260–61
- Celia, C 385
- cell therapy 198, 205
- Chaloff, J 127
- Chan, M 452
- Chanda, R 466
- Chapman, S 348
- Chaudhry, F 470

- chemical or biological agents 323
- Cheng, F 430
- children
  - alcohol 372, 389–91
  - compulsory vaccination 335–6
  - consent 236
  - food 399, 408, 417–18
  - medication 25, 161
  - obesity 407, 408
  - product placement 390–91
- Chile 466
- China 334, 441
- Christiansen, EC 471
- chronic conditions 35
- Cisneros, J 60
- Cisneros Örnberg, J 386
- citizen science *see* biomedical research
  - law and policy and citizen science
- citizens' initiative: 'One of Us' 204, 220
- Clemens, J 459
- Clemens, T 243
- climate change 325
- clinical research/trials 99, 137, 138, 148, 158, 188, 240–41, 458
  - database 226
  - ethical rules 476
  - human dignity 493–4
  - infrastructures 204–5
  - marketing authorisation 162, 166, 216, 226–7
  - multi-centre 145
  - post-marketing duties 169
  - trade law 448
- cloning 89, 202–3, 207, 461, 493–4
- co-infections 334
- codes of conduct 390, 417–18
- Coggon, J 454
- Cogliani, C 420
- Cohen, IG 60, 453, 471, 472
- Cole, M 274
- Collins, D 465
- colourants in foodstuffs 24
- Commission 39–40, 42–3, 311
  - agencies and networks 44
  - alcohol 381, 383–4, 386, 389, 390, 392, 394, 395, 396–7
  - citizen science 149
  - communicable diseases 322, 323, 326, 327–8, 334
  - competition law and policy 270–72, 273, 275–6, 277, 280, 281–8, 289
  - Country Reports 293
  - diet, physical activity and health 408, 418
  - digital agenda 145
  - eHealth 243, 247, 252
  - Europe 2020 strategy 144, 146
  - Eurozone crisis 123, 292, 293, 299, 300, 303, 304, 305, 306–7, 491
  - food law 403, 408–9, 410, 411, 413, 415–16, 417
    - antimicrobial resistance 421
  - fundamental rights 106–7
  - global health law and policy 456, 468
  - health professions 116, 303, 304
  - human materials 222, 230, 233, 234
  - infringement procedures 58
  - new health technologies 197, 216–17, 218, 219, 220
  - Patients' Rights Directive 45, 46–7, 50–51, 52–5, 57–8
  - pharmaceuticals 159, 163–4, 165, 166, 184–5, 305, 306–7, 494
    - competition law 275–6, 282–3, 289
  - research 491
  - tobacco 356, 359, 360
  - trade law 433, 434–5, 436, 437, 440, 442, 443, 444, 445, 450, 451, 452
- common agricultural policy (CAP) 332, 408
- common commercial policy (CCP) 432, 434
- communicable diseases 315–46
  - definition 317
  - food law and traceability 336–7
  - freedom of movement 337–40
  - Health Security Committee 322, 326, 334
  - historic development 318–25
  - integration 316, 318, 320, 322, 345
  - liability for harm 332, 340–41
  - precautionary measures 316, 330, 331–3, 340, 345
  - state-of-the-art: control
    - health threats: all-hazards approach 325–6
    - measures 331–44
    - players and principles 326–31

- surveillance system 261, 317, 321–2, 326, 346
- vaccination 316, 317, 333–6
- competition law and policy 19, 267–90, 494, 495
- cartels and dominance 270
  - NCA, role of 278–80
  - no special status for healthcare 270–77
  - services of general economic interest (SGEI) 277–8
- efficiency concept 268–9
- merger control 280–83, 288
- State aid 283
  - case law 286–8
  - SGEI and financing healthcare 283–6
- undertakings 269
- Conant, L 60, 71
- confidentiality 167, 171
- eHealth 245, 256, 257, 262
- control 482, 493
  - clinical trials 99
  - dynamic 237
  - eHealth 245, 257–9
  - human materials 236–7, 238, 241
- consequentialism 80
- 'constitutional asymmetry' 9, 20, 490
  - European Medicines Agency (EMA) 44
  - see also* values in EU health law and policy
- consumer choice 169, 362
- consumer law 115
  - contracts 249–50
- consumer protection 174, 182, 332, 417
- consumer safety 316, 336
- consumer welfare 267, 269, 270, 272–3, 283
- Consumers, Health, Agriculture, and Food Executive Agency (CHAFAEA) 43
- contagious diseases *see* communicable diseases
- contract disputes
  - eHealth: applicable law 249–50
- Conway, G 67
- COREPER (Committee of Permanent Representatives) 40
- Cornelissen, R 309
- Correa, C 465
- Correia, T 112
- corruption 129
- Council of Europe 85, 88, 172, 236, 238, 240, 241, 461, 482
- Council of the European Union 39, 40–43, 480, 485–6
  - alcohol 381–2, 383, 394
  - antibiotics and food-producing animals 421–2
  - communicable diseases 322, 344
  - Country-Specific Recommendations (CSR) 293, 296, 300
  - development policy 459–60
  - medical devices 219
  - nutrition and physical activity 408
  - Patients' Rights Directive 45, 47, 49–52, 53–5
  - qualified majority vote 52, 352, 354, 434, 435
  - tobacco 354–5, 360, 366
  - trade policy 434, 435
  - unanimity 434
  - values and principles 308–9
- counterfeit
  - Anti-Counterfeiting Trade Agreement (ACTA) 434
  - medicines 252–3, 254
- country-specific recommendations (CSRs) 34
- Court of Justice of European Union (CJEU) 39, 60–62, 80–81, 199, 354, 434, 479, 480, 486, 490, 495
  - agenda setting 320
  - alcohol 370, 374–80, 387–8, 391, 392, 393–4, 481
  - annulment action 95–6, 354–5
  - biotechnologies, research in 208–10, 220
  - communicable diseases 328–33, 340, 341, 345
  - competition law 267, 268, 269, 270, 271, 272–5, 276, 277–8, 279
  - merger control 281
    - State aid and SGEI 284, 286
  - dental treatment 58, 75
  - distinction between public health and healthcare 21
  - ECTHR and 77–80, 81, 85–6

- expulsion of person with serious illness 340
- food 402, 424, 425, 430
- fundamental rights 79–80, 87, 91, 105–6, 108, 341–4, 387, 483
  - access to healthcare: challenges to national legislation 100–102
  - dignity 88, 96–7
  - free movement, limitations on 102–6
  - general principles of EU law 84–5, 94
  - non-discrimination 97–8, 342–3
  - personal data 99
  - review and interpretation 95–9
- human materials 235, 239
- Internet sales 253–4
- Member States and 71–7, 354
  - principal and trustee 72, 76–7, 81
- national courts and 61, 62–70, 80
  - frequency of requests for preliminary rulings 65–7
  - judicial review traditions 63–5
  - proportionality 67–9
- patient mobility case law 29, 30–31, 45–6, 49, 50–51, 52–3, 55, 58–9, 91, 246
  - Member States and CJEU 73–6
- pharmaceuticals
  - advertising 168
  - Internet sales 253
- precautionary measures 332–3, 345
- preliminary reference 61, 62–70, 80, 95, 96–7, 359–60
- product liability 174, 176–80, 182, 191, 193, 194, 195–6, 260
  - development risks 181, 191–2
- removal of person with serious illness 340
- risk assessment and management 328–31
- tobacco 354–5, 357, 359–60, 366–7
- trade law 433
- vaccination 335
- courts 60–62
  - Court of Justice of European Union (CJEU) *see separate entry*
- Craig, P 356
- Cremona, M 463
- Creuzfeld-Jacob Disease, new variant/bovine spongiform encephalopathy (BSE) 24, 38, 40, 138, 233, 316, 321, 323, 328, 333, 336, 340, 342, 381, 398–9, 400
- Croatia 232, 297–8
- Cuocolo, L 411
- Curtin, D 492
- customary international law 85
- Cuvillier, A 157, 167
- cybercrime 257
- Cyprus 232, 420
- Czech Republic 50–51, 57, 119, 125
- Daniels, N 454
- data protection 85, 98–9, 202, 461, 476, 483
  - ePublic health technologies 262
  - mHealth 256–9
- Dauses, MA 84
- Davey, M 467
- Davies, G 31, 62, 68, 69, 72
- Davies, H 117
- Dawes, A 31
- Dayen, D 468
- De Búrca, G 67
- De Ville, F 447, 468
- De Witte, B 357
- decision-making, fractured 6–7
- defective products *see* product liability
- democracy 152, 463, 485, 495
  - see also* biomedical research law and policy and citizen science
- Denmark 12, 125, 420
  - Patients' Rights Directive 49, 57, 58
- dentists/dental treatment 58, 75
  - qualifications 117, 118
- developing countries 348, 455, 471, 475–6
  - technical assistance 465, 472
- development policy and human rights 472–3
- development policy and trade 459–60, 462–70
- Devon, R 138
- diabetes 159, 202, 405, 407
- Dickens, B 238
- diet-related diseases *see* nutrition/diet-related diseases
- diets 20

- digital agenda 144–5  
 biomedical research, open science  
 and 145–7
- dignity 13, 79–80, 96–7, 238, 480, 482  
 constitutional setting of EU 493–4,  
 495  
 fundamental rights 88–9, 486,  
 487–8
- Dinan, D 23
- dioxins 404
- direct effect 84
- discrimination 202, 302, 306, 316, 444  
 CFREU 91–4, 97–8, 100, 342–3  
 communicable diseases 338  
 indirect 50  
 reverse 51  
 sex 85, 98
- doctors 280  
 mobility *see* health professional  
 mobility  
 qualifications 117, 118  
 working time 28, 116, 117
- Doha Declaration (2001) 464–5
- domicile 249, 250
- Dorbeck-Jung, B 198
- Doubleday, R 142, 153
- Douglas-Scott, S 493
- Drescher, LS 411
- Dugard, J 471
- Duguet, AM 248
- Dunne, P 343
- Dupré, C 88
- Dussault, G 111, 112, 122, 123, 133,  
 304
- Dute, J 323
- Duxbury, N 239
- e-cigarettes 355, 359
- e-health *see* eHealth
- Eberlein, B 44
- Ebola 262, 316, 322, 323, 328, 337,  
 338, 341, 458
- Eckes, C 86
- Economic Free Trade Area 118
- Edinger, WWH 405, 406, 412, 424
- education 115, 118, 119, 125, 126,  
 129–30, 418  
 alcohol 395  
 Internet 248  
 mobile health apps 255  
 obesity 407  
 tobacco 362, 366
- Eeckhout, P 86, 456, 485
- eHealth 33, 149, 242–63, 300, 438  
 Action Plan 2012–2020 245  
 definitions 243  
 electronic health records (EHRs)  
 244, 261  
 cross-border access to 246–50  
 ePrescriptions and ePharmacies 244,  
 245, 250–54  
 ePublic health technologies 261–2  
 liability issues 249–50  
 mobile health apps 244–5, 245–6,  
 254–61
- Eide, A 474
- Eleftheriadis, P 454, 460
- Elsmore, MJ 27
- embryos, human 96–7, 202–4, 207,  
 208–10, 220, 235
- emergency management 325–6
- emerging economies 348  
*see also* developing countries
- Emerson, M 435
- environment 332  
 environmental events 323, 325
- ePharmacies 245, 252–4
- ePrescriptions 244, 250–52, 254
- Epstein, S 134, 142
- equality/inequality 13, 107, 473, 474–5,  
 480, 482  
 constitutional setting of EU 491,  
 492, 494
- eHealth 248  
 fundamental rights 91–4, 341, 486,  
 487–9  
 health professional mobility 112,  
 132, 133
- equity 308, 309, 480
- Erin, C 239, 240
- Estonia 297  
 health professional mobility 119–22
- ethics 443, 454, 468, 474, 480, 482,  
 483–4, 492–3  
 biomedical research 135, 136, 138,  
 139, 141, 152, 153, 155  
 human materials 226, 235, 236–7,  
 240–41  
 new health technologies 201–2,  
 210, 220, 344

- human materials 226, 234–41
- precautionary principle 332, 340
- recruitment of health personnel 122–3
- see also* morality
- eugenics 482, 493
- Europe 2020 33, 144, 146
- European Advanced Translational Research Infrastructure in Medicine (EATRIS) 205
- European Agency for Health and Safety at Work 31, 43
- European Central Bank (ECB) 123, 292
- European Centre for Disease Prevention and Control (ECDC) 31, 43, 322–3, 326–7, 334, 336, 345–6, 458
- European Clinical Research Infrastructures Network (ECRIN-ERIC) 204–5
- European Council
  - alcohol 381
- European Court of Human Rights (ECtHR) 61–2, 67
  - CJEU and 77–80, 81, 85–6
  - communicable diseases 339–40
  - informed consent 493
- European Environment Agency (EEA) 31, 43, 321
- European Financial Stabilisation Mechanism 293
- European Financial Stability Facility 292–3
- European Food Safety Authority (EFSA) 24, 43, 400, 415, 416
- European Group on Ethics in Science and New Technologies (EGE) 136, 152, 153, 332, 340
- European Medicines Agency (EMA) 31, 43, 44, 169, 305
  - Committee for Advanced Therapies (CAT) 216, 225
  - marketing authorisation 159, 163–4, 165–7, 226
  - new health technologies 212, 214, 216, 225
  - transparency 171
  - vaccines 334
- European Monitoring Centre for Drugs and Drug Addiction 31, 43
- European Parliament 29, 39, 40, 41–3
  - alcohol 382
  - antibiotics and food-producing animals 421–2
  - communicable diseases 322
  - human materials 239
  - medical devices 219
  - mHealth data 258
  - nutrition and health claims 416
  - Patients' Rights Directive 45, 46, 47–9, 52, 53–5
  - rapporteurs 42, 43, 48, 49, 52
  - shadowrapporteurs 42, 43, 48, 49, 52
  - tobacco 354–5, 360, 366
  - trade policy 434–5, 451, 452
- European People's Party (EPP) 48, 49, 56
- European Semester 22, 33–4, 293, 294, 295, 296, 492
- European Stability Mechanism (ESM) 292–3, 491–2
- Eurocepticism 12, 65
- Eurozone crisis 268, 291–312
  - access to healthcare 295–300, 307, 309–10, 311
  - direction of travel 308–11, 312
  - economic governance instruments 118, 292–4, 300, 491–2
  - free movement of healthcare professionals 291, 299, 300–305, 308, 311
  - Memorandums of Understanding (MoUs) 292–3, 295, 298, 300, 305, 491–2
  - regulation of medicines 291, 299, 305–8, 311
  - see also* health professional mobility
- euthanasia 61
- Evans, R 140
- evergreening of patents 470
- Everson, M 31
- expulsion
  - inhuman and degrading treatment 339–40
- den Exter, A 460
- external dimension 22, 30, 34, 118
  - global health law and policy, EU's emergent 453–76



- human rights 454, 460–61, 463, 470–5
- institutional architectures 456–62
- trade/development 459–60, 462–70
- trade and health *see separate entry*
- Eysenbach, G 244
- Fägersten, B 463
- Faid, M 353
- Fairchild, AL 315
- Fairgrieve, D 182, 187
- Falkner, G 73
- Farrell, AM 227, 228, 329
- Favale, M 214
- Fearnley, L 325
- Feldman, EA 348, 350, 351
- Feldschreiber, P 158, 166
- Fenton, E 484
- Fidler, DP 323
- Fiedziuk, N 269
- financial crisis 33, 35, 122, 144
  - see also* Eurozone crisis
- Finland 58, 119, 172, 420
- Fiorini, DJ 138
- fish stocks 342
- Flear, ML 67, 135, 136, 145, 146, 150, 151, 197, 212, 214, 220, 317, 321, 328, 342, 476
- Flood, CM 453
- flu 34, 316, 322, 323, 327, 334, 340
- Fontanelli, F 100
- Food and Agricultural Organisation (FAO) 34, 458
- food law 24–5, 59, 316, 398–425, 455, 475
  - antimicrobial resistance (AMR) 399, 419–23, 430, 445
  - Transatlantic Taskforce on 447
  - Codex Alimentarius* 430
  - Commission 458–9
- food, safety and health 400–406
  - hazard 405–6
  - injurious to health 404–6
  - unsafe feed 404
  - unsafe food 401–4
- nutrition and public health 406–9
  - advertising and marketing:
    - children 417–18
    - nutrition and health claims 99, 105–6, 386–9, 399, 408, 414–17
    - nutrition labelling 409–13
    - portion sizes 413, 417
    - and traceability 336–7
    - TTIP 431
    - who should regulate 423–5
- Forman, L 471
- Forst, R 485
- Fortun, M 141
- Fortunato, E 126, 128
- Foucault, M 137, 142, 143
- Fox, DM 339
- France 29, 71, 218, 298, 340, 343
  - health professional mobility 119, 124, 129
  - HIV-infected blood 227
  - Patients' Rights Directive 49, 58
  - pharmaceuticals 187–8
- Francioni, F 220
- Francis, J 41
- fraud 247–8, 252, 261
  - food 404
- free movement of capital 23
- free movement of goods 23, 39, 46, 316
  - alcohol 370, 374–80, 391, 393–4
  - blood products 239
  - food 400, 411, 423–4
  - national courts and CJEU 68–9
  - protection of human life and health 68–9
  - tobacco 27, 352
- free movement of persons 302–3, 316
  - communicable diseases 337–40
  - workers 23, 28, 36–7, 45
  - health professional mobility *see separate entry*
- free movement of services 23, 28–9, 39, 46, 302–3
  - abortion 66
  - IVF: export of sperm 69
  - Patients' Rights Directive 29, 32–3, 74
- free trade agreements 373, 431–2, 438, 466, 469–70
  - deep and comprehensive 466
  - EU-Caribbean 443
  - EU-Japan 435
  - EU-Korea 443, 472
  - EU-Singapore 438, 442

- freedom of establishment 23, 33, 302–3
  - public health as fundamental right 102–3, 105, 106
- Freeman, B 363
- Freeman, M 453, 484
- Friant-Perrot, M 388
- Frischhut, M 317, 333, 342, 343, 344, 480, 482, 493
- fundamental rights 20, 82–108, 362, 484
  - Charter 20, 29, 34, 37, 77, 82–3, 87, 92–3, 202, 341–4, 460–61
  - Art 1: human dignity 88–9
  - Art 3: physical and mental integrity 89–90, 236, 238, 341, 461, 493
  - Art 17: right to property 341, 342
  - Art 20: equality before the law 91–4, 341
  - Art 21: non-discrimination 91–4, 97–8, 100, 343
  - Art 35: healthcare 37, 78–80, 90–91, 98, 100–106, 108, 341, 342, 343, 387, 460
- ECtHR and CJEU 77, 85–6
- health values and 483–5
- health values in 485–90
- interaction between health law and policy and 94
  - access to healthcare: challenges to national legislation 100–102
  - policy developments 106–8
  - public health as fundamental right 102–6
  - review and interpret EU legislation 95–9
- overview 83, 87
  - Art 6 TEU 83–4
  - ECtHR 85–7
  - general principles of EU law 83, 84–5, 87, 94
  - health topics potentially affected 92–3
- Fundamental Rights Agency (FRA) 107–8
- Galan, A 129
- Galligan, D 139
- Garde, A 354, 357, 379, 390, 402, 405, 408, 424
- Garrett, G 71
- GATS (General Agreement on Trade in Services) 433, 439–40, 442, 443, 444
- GATT (General Agreement on Tariffs and Trade) 429
- Geber, F 381
- gene therapy 198, 205, 213, 215, 494
- general principles of EU law 83, 84–5, 87, 94, 354, 486
  - proportionality *see separate entry*
- genetic research 148
- genetic testing 89, 461
- genetically modified organisms (GMOs) 138
- genotoxic carcinogens 404
- George, C 254
- Georgia 466
- Germany 71, 76, 298
  - Constitutional Court 64–5
  - haemophiliacs 227
  - health professional mobility 119, 124, 129, 130–31, 303
  - human dignity 88
  - Patients' Rights Directive 49, 51
  - pharmaceuticals 187
  - strict liability 172, 174
  - tobacco 354–5
  - TTIP 446
- Gibbon, S 142
- Giesen, D 227
- Giesen, I 173
- Gilabert, P 485
- Gilmore, A 397, 475
- Glinos, IA 111, 112, 118, 119, 122, 123, 129, 130, 303, 304
- Global Alliance for Vaccines and Immunisation 118, 459
- Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria 118, 338, 459
- global health law and policy, EU's emergent 453–76
  - human rights 454, 460–61, 463, 470–75
  - institutional architectures 456–62
  - trade/development 459–60, 462–70
- Global Health Security Initiative 339
- globalisation 34, 490
- Goffman, E 349

- Gold, R 238  
 Goldberg, RS 183, 184, 187, 190, 200  
 Golub, J 65  
 González Vaqué, L 410  
 Gormley, L 26  
 Gostin, J 262  
 Gostin, LO 315, 453, 454, 457, 462  
 governance and legislative politics  
   36–59  
   conclusion 55–9  
   Patients' Rights Directive 39, 40, 45  
   agenda-setting 45–7  
   inter-institutional negotiations  
     52–5  
   political negotiations 47–52  
   political institutions 39–44  
 Gragl, P 86  
 Grant, W 323  
 Greece 51, 232, 297–8  
   health professional mobility 122, 303  
 Greer, SL 18, 20, 21, 22, 33, 34, 35, 39,  
   40, 59, 111, 112, 113, 116, 132,  
   318, 320, 344, 345, 365, 381, 435,  
   458, 464, 476  
 Grevi, G 463  
 Grimm, D 490, 492  
 van de Gronden, JW 269, 277, 279,  
   280, 281, 282, 283, 285, 310, 464  
 Guigner, S 339  
 Gusfield, JR 368  
 Gusma'o, R 144
- H1N1 325, 334–5, 458  
 H5N1 334  
 habitual residence 249, 250  
 haemophiliacs 227  
 Haffey, F 259  
 Hager, C 113, 114  
 Hammond, D 348  
 Hancher, L 19, 33, 47, 53, 270, 302  
 Hancox, E 100  
 Hardcastle, R 238  
 Harmon, SHE 208  
 harmonisation 30, 37, 167, 254, 309,  
   468, 469  
   agencies and networks 44  
   alcohol 381, 384, 386–91, 392, 393  
   communicable diseases 316  
   food law 411, 417, 424, 425, 459  
   human materials 226, 241  
   medical devices 26  
   minimum 26  
   pharmaceuticals 25, 458  
   product liability 174  
   tobacco 27, 356, 357, 358, 360, 366,  
     367, 381  
     excise duties 351  
 Harrington, J 454, 460  
 Harrison, JP 243  
 Harrison-Dunn, A-R 416  
 Van Harten, G 450, 451  
 Hartlapp, M 39  
 Harvey, A 152  
 Hatzopoulos, VG 30, 53, 76  
 health professional mobility 111–33,  
   438, 447  
   asymmetric flows 115–16, 118,  
     119–22, 124–5, 126–31, 132  
   bilateral agreements 127, 131  
   case studies  
     Italy, foreign nurses in 125–8  
     Portugal 123–5  
     Romanian doctors 128–31  
   circular migration 131  
   doctors 114, 116, 117, 118, 119,  
     123–5, 126, 132, 303  
     Romanian 128–31  
   Eurozone crisis 291, 299, 300–305,  
     308, 311  
   facts and figures 118–23  
   needs-based distribution 133  
   nurses 1, 114, 116, 117, 118, 119,  
     123–4, 132, 303  
     Italy 125–8, 303  
   recruitment practices 122–3, 131  
   regulation and policy 115–18  
   regulatory gap 113  
   short-term movements 122  
   trade 436–7  
 health, right to 453, 460, 472, 473–4  
   CFREU: Art 35 37, 78–80, 90–91,  
     98, 100–106, 108, 341, 342, 343,  
     387, 460  
   collective 474  
 health and safety at work 28, 37  
   European Agency for 31, 43  
 healthcare distinguished from public  
   health 21–2  
 Heath, D 154  
 Hedgecoe, A 141

- Hein, W 465, 471  
 Hendriks, A 460  
 Hennette-Vauchez, S 200  
 herbal medicines, traditional 161  
 Hernández, G 385  
 Hervey, TK 17, 18, 19, 20, 22, 24, 32, 34, 35, 38, 39, 55, 58, 59, 60, 67, 69, 76, 78–9, 82, 94, 95, 99, 104, 105, 112, 113, 114, 115, 116, 117, 118, 132, 136, 146, 158, 164, 169, 200, 208, 214, 217, 234, 239, 269, 289, 296, 310, 321, 322, 328, 329, 333, 335, 342, 343, 353, 355, 357, 365, 381, 398, 424, 453, 459, 460, 462, 463, 464, 465, 466, 468, 472, 474, 475, 480, 482, 487, 489, 490, 492, 494  
 Heymann, D 338  
 Hilgartner, S 143  
 history and scope of EU health law and policy 23, 35  
   1957–1992 23  
     food law 24–5  
     free movement of services 28–9  
     health and safety at work 28  
     medical devices 26–7  
     medical qualifications 28  
     pharmaceuticals 25–6  
     social security coordination 23–4  
     tobacco 27  
   1992–2007  
     agencies 31  
     integration context 29  
     open method of coordination and health 31–2  
     patient mobility case law 30–31  
     public health 29–30  
   2007 to present 32  
     European Semester 33–4  
     freedom of establishment 33  
     freedom of services: Patients' Rights Directive 32–3  
     global context 34  
     third health programme and Europe 2020 33  
 HIV/AIDS 107, 118, 134, 159, 227, 316, 321, 340, 342–3, 459, 471, 474  
 Hobolth, M 44  
 Hodges, C 181, 218  
 Hoffman, S 261  
 Hogg, PW 74  
 homeopathic remedies 161  
 Horizon 2020 146, 150, 201–3, 204  
 horsemeat scandal 404  
 Howells, G 178, 181, 189, 191, 351, 354, 356, 366  
 human cloning 89, 202–3, 207, 461, 493–4  
 human dignity 13, 79–80, 96–7, 238, 480, 482  
   constitutional setting of EU 493–4, 495  
   fundamental rights 88–9, 486, 487–8  
 human Embryonic Stem Cells (hESCs) 202–4, 208–10, 220  
 human materials 199, 222–41, 316, 455  
   commodification 238–9, 241, 471–2, 495  
   cross-border exchange of 232–4  
   ethical aspects of 234–40  
   legal classification of 224–7  
   quality and safety of 227–31  
   rapid alert systems 230–31  
   traceability 229, 230, 233  
   tissues and cells 231  
 human rights 20, 62, 64, 91–4, 132, 325, 481, 482, 483–5, 487  
   communicable diseases 316, 339–40, 341–4, 346  
   ECtHR 61–2, 67, 339–40, 493  
   CJEU and 77–80, 81, 85–6  
   eHealth 242, 245  
   general principles of EU law 84–5, 87  
   global health law and policy 454, 460–61, 463, 470–75  
 Hungary 51, 297  
   health professional mobility 119–22, 125  
 Iceland 420  
 identity and health law 60–61, 63  
 Iglesias, R 348  
 immunisation 118, 316, 317, 333–6, 459  
 India 466  
 individualism 63–5  
 inequality *see* equality  
 infectious diseases 145, 317  
   communicable diseases *see separate entry*

- mobile health apps 255
- influenza 34, 316, 322, 323, 327, 334, 340
- information
  - alcohol 374, 385, 386–9, 395
  - asymmetries 364
  - communicable diseases 261–2, 317, 320, 323
  - eHealth 245, 246–50, 256–7, 261–2
  - food 409–13
    - nutrition and health claims 414–17
  - health technology assessment
    - network 310
  - human materials
    - consent 236, 237
    - organ transplantation 229, 230, 233, 237
    - rapid alert systems 230–31
  - medicines 170, 186
    - confidentiality 171
    - labelling and packaging 167–9
  - TiSA 445
  - tobacco 347, 351, 362–3, 364–5, 367
- Inglese, M 104
- inhuman and degrading treatment 339–40
- innovation union 144
- Innovative Medicines Initiative (IMI) 205, 210
- insurance 98, 272, 443, 445
- intellectual property 431, 433, 438, 450
  - patents *see separate entry*
  - TRIPS Agreement 433, 464–5, 470, 472, 475
  - TTIP 445–6, 447–8
- ‘interface’ between EU law and health law 18–19
- intergovernmentalism 71, 311
- internal market/single market 19, 20, 21, 22, 40, 468, 479, 481–2, 489–90
  - alcohol 374–80, 381, 382, 383, 386–91, 392, 393–4, 395
  - communicable diseases 341–2, 346
  - competition law 267, 268, 270, 272, 273, 280, 288
  - ‘constitutional asymmetry’ 9, 20, 44, 490
  - Digital Single Market (DSM) 144–5, 242–3
  - eHealth 242
  - food law 417, 422, 425
  - human materials 234, 239
  - human rights 77–8, 79–80, 81, 474–5
  - medical devices 26
    - mobile health apps 255
  - medical qualifications 28
  - new health technologies 199, 211
  - open science 147
  - Patients’ Rights Directive 32, 47, 48, 56, 246
  - pharmaceuticals 163–7
  - public health as fundamental right 102–6
  - research 147, 150, 151
  - tobacco 18, 76, 352, 354–6, 357–8, 359, 360, 366–7, 481
  - trade law 435–7, 438, 447
  - see also* free movement of capital; free movement of goods; free movement of persons; free movement of services; freedom of establishment
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 12, 158, 226, 455, 458
- international law 82, 84–5, 88, 91, 329, 432, 454, 467, 473
- International Monetary Fund (IMF) 123, 292, 295, 455, 473
- Internet 418
  - eHealth *see separate entry*
  - risk/benefit of pharmaceutical products 169
- interpretations of EU health law and policy 17–18, 35, 235
  - ‘constitutional asymmetry’ 9, 20, 44, 490
  - health as ‘implicit’ or ‘explicit’ characteristic 19
  - ‘interface’ between EU law and health law 18–19
  - other 20
- investment court system 443, 450
- investment protection 433, 435, 438, 439, 442, 443, 444, 445, 446, 452
  - arbitration, ongoing legal uncertainty and 448–51

- Ireland 286, 295, 297–8, 308, 360  
 health professional mobility 119, 122, 303  
 Patients' Rights Directive 51  
 Supreme Court and CJEU 66–7  
 irregular migrants 107  
 Irwin, A 135, 141, 142  
 Italy 297, 298, 420  
 health professional mobility 122, 125–8, 303
- Jackson, E 158, 164, 169, 170, 171, 454, 464, 472  
 Jacobsen, N 88  
 Jahns, R-G 255  
 Janson, J 395  
 Japan 212, 435  
 Jarman, H 431, 435, 443, 449, 464  
 Jasanoff, S 138, 139, 143, 333, 492  
 Jensen, JD 418  
 Jensen, MD 43  
 Jernigan, DH 373  
 Jha, P 348  
 joint decision trap 73–4  
 Jones, A 270  
 Jones, J 88  
 Jordans, F 349  
 Jowell, J 150  
 Jowett, M 298, 300  
 Judge, D 43  
 judicial process 85  
 judicial review  
 'dialogue' 74  
 national traditions 63–5  
 Judt, T 23  
 Juncker, JC 436
- Kaiser, W 23  
 Karanikolos, M 342  
 Kattelus, M 58  
 Kaye, J 237  
 Kende, MS 471  
 Kerr, A 142  
 Kickbusch, I 458  
 Kierkegaard, P 242  
 Kim, S 349  
 Kingdon, JW 318  
 Kinney, ED 482  
 Kirby, KN 365  
 Kirwan, L 413
- Kloka, M 51  
 Knightley, P 157, 172  
 Knorr Cetina, K 139, 142  
 Knowles, LP 235, 484  
 Koenigstorfer, J 411  
 Kohler-Koch, B 31  
 Koivusalo, M 383, 431, 438  
 Kok, W 144  
 Kolčić, I 112  
 Kommers, D 61  
 Korea 443, 472  
 Kosta, V 86  
 Kostera, T 52  
 Kovziridze, T 469  
 Krajewski, M 439, 457, 464  
 Kramer, EB 471  
 Kranenborg, H 99, 461  
 Kroezen, M 112, 129  
 Krugman, P 60  
 Kuhlmann, E 112, 113  
 Kukafka, R 261  
 Kulyk, O 261  
 Kumarasamy, K 445  
 Kumm, M 366
- labelling  
 alcohol 372, 374, 394  
 human materials 229  
 nutrition 399, 408, 409–13  
 and health claims 414  
 pharmaceuticals: packaging and 162, 163, 164, 166, 167–9, 186, 188  
 tobacco 27, 351, 358–9, 360, 362–5, 366  
 traffic light 411–12
- Lafortune, G 130  
 Lakoff, A 325  
 Lamb, D 239  
 Lamping, W 17, 35  
 Lang, JT 267  
 Latin America 119  
 Latour, B 139  
 Latvia 57, 297–8  
 Lear, J 269  
 Lee, M 198  
 Leenen, HJ 482  
 van Leeuwen, B 185  
 legal personality, international 456  
 Legemaate, J 482

- legislative politics 44  
 conclusion: how legislative output  
 conditions outcomes 55–9  
 Patients' Rights Directive 39, 40, 45  
 agenda-setting 45–7  
 inter-institutional negotiations  
 52–5  
 political negotiations 47–52
- Lemke, T 142
- Lenaerts, K 100
- Lenze, S 187
- Leone, C 112, 124
- Lessig, L 140
- Levy, S 420
- Lewis, TL 259
- Lexchin, J 443
- LGBT (lesbian, gay, bisexual and  
 transgender) individuals 107
- Liao, SM 485
- liberalism, modified or embedded  
 462–3, 465, 466, 469, 470, 475
- libertarian paternalism 367
- licensing of health professionals 248–9
- Lidskog, R 141
- Lithuania 51, 298
- Little, JW 179
- Lock, T 86
- London, L 454
- Loring, B 409
- Lovells 183
- Lupton, D 143
- Luxembourg 58
- Lyon-Caen, G 393
- m-health 149, 244–6, 254–61
- McCambridge, J 373
- McCann, MT 417
- McGrady, B 353, 362, 374
- McGuinness, S 471
- McGuire, AL 242
- McHale, JV 236, 482, 487, 493
- McKee, M 326, 337, 476
- MacKenzie, D 139
- Macmaoláin, C 400, 413, 421, 424
- McNaghton, P 136
- Maggetti, M 44
- Mahalatchimy, A 214, 221, 226, 235
- Maier, CB 113, 114, 118, 119, 122
- mainstreaming of health 19, 30,  
 382–91, 462
- Mak, C 483
- Mäkinen, M 251
- malaria 118, 459
- Maletic, I 393
- Malgieri, A 114, 116, 133
- Malta 57
- Mandel, GN 138
- Mann, JM 454
- Marco Colino, S 270
- Margelis, G 244
- margin of discretion 377, 378, 388
- Markel, H 334
- marketing  
 of alcohol 372, 386–8, 389–91, 394  
 of food 399, 408, 417–18  
 of tobacco 362, 367
- Marmot, M 395
- Martens, M 44
- Martin, R 327, 329
- Martin-Casals, M 174
- Martinsen, DS 38, 45, 46, 47, 48, 50,  
 52, 57, 59, 72, 74, 479
- Matthews, D 465, 472
- Matthews, P 238
- Mattli, W 71
- Mattoo, A 437
- Med 2.0 142
- medical devices 26–7, 38, 44, 59, 177–8,  
 185, 188, 191, 194, 195, 455  
 definition 255  
 human materials 227  
 Internet sales 253  
 mobile health apps 245–6, 255–6,  
 259  
 new health technologies 211, 215,  
 217–19, 220–21  
 trade law 438
- medicinal products 25–6, 59, 145, 227,  
 231, 240, 455  
 advanced therapy *see separate entry*  
 arbitration 450  
 competition law 272, 273–6, 279,  
 289  
 merger control 281, 282–3  
 definition of 157–8, 211  
 developing countries 475  
 EU regulation 157–71, 291, 299,  
 305–8, 311, 494  
 impact on civil liability *see below*  
 interactions

- labelling, packaging and advertising 162, 163, 164, 166, 167–9
- marketing authorisation *see below*
- post-marketing duties 169–70
- transparency 170–171, 192
- vaccines 334
- European Medicines Agency *see separate entry*
- generic 274, 275–6, 282, 300, 305, 307, 442–3, 447–8, 470
- ICH 12, 158, 226, 455, 458
- Innovative Medicines Initiative (IMI) 205
- interactions between regulation and civil liability 182–96
  - causation and recoverable damage 194–5
  - defectiveness enquiry 182–91
  - development risks defence 191–2
  - ‘put into circulation’ 193–4
  - reciprocity 195
- Internet 169, 245, 252–3, 254
- marketing authorisation 25, 158–67, 220–21, 458
  - centralised procedure 159–61, 165–7, 169, 212–17
  - human materials and medicinal products 224–7
  - impact on civil liability 182–96
  - individual Member State application 159, 161–3
  - mutual recognition and decentralised procedure 159, 163–5
  - post-authorisation safety studies 163, 166
  - time limits 162, 163, 164, 165, 166, 214
- marketing and post-market control 156–96
  - EU regulation 157–71, 212–17, 220–21
  - interactions 182–95
  - product liability 172–82
- pharmacovigilance 162, 163, 169–70, 195, 216, 230
- pricing and TTIP 445, 446, 447–8
- product liability 172–4, 249
  - defect 173, 176–80
  - development risks 180–82
  - interactions with regulation 182–96
  - scope and structure 175–6
- trade law 438, 445, 450
  - generic medicines 442–3, 447–8
  - TTIP 445, 446, 447–8
- TRIPS Agreement 464–5, 470, 472, 475
- unauthorised drugs
  - terminal illness 78
- Meisterernst, A 417
- Mellina, C 127
- Member States 30, 37, 44, 305–6, 307, 366
  - alcohol 369–70, 391–4, 396, 397
  - control policies and EU internal market 374–80
  - international public health context 370–74
  - antimicrobial resistance 420–21, 447
  - CJEU and 71–7, 81, 354
  - food 399–400, 411, 423–5
  - international treaties 456
  - National Competition Authorities (NCAs) 271–2, 273, 278–80, 289–90
    - merger control 280–82, 283
  - State aid 31, 283–8
  - tobacco 352
  - trade and health 429, 431, 432–3, 438, 442, 445, 451, 452
  - national parliaments 435
  - values 482–3, 494–5
    - EU constitutional setting 490–94, 495
    - and fundamental rights 484–7
  - see also* Eurozone crisis; national courts
- Menéndez, AJ 87, 484
- mental disorders 407
- mental health care 107
- mentally incapable adults
  - clinical trials 99
- Mercurio, B 465
- merger control 280–83, 288
- methyl mercury 404
- van der Meulen, B 24, 400, 402, 404
- mHealth apps 149, 244–6, 254–61
- Michalowski, S 90, 335, 461



- Micklitz, HW 329  
microbiology 317, 326  
midwives 117, 118  
Mildred, M 182, 185, 187, 189, 190  
Miller, CJ 183  
Miller, D 373  
Milward, AS 23  
Mladovsky, P 298  
Mnookin, RH 61  
mobile health apps 149, 244–6, 254–61  
  liabilities 259–61  
Moir, H 470  
Moldova 466  
Montgomery, J 454, 460  
Moodie, R 373, 396  
Mooij, B 268  
morality 207, 208, 210, 340  
  *see also* ethics  
Moravcsik, A 71  
Morrison, M 203  
Mossialos, E 17, 18, 21, 45, 113, 132,  
  269, 303, 326, 476, 482  
Mounier-Jack, S 327  
Muir, E 484  
Mukherjee, JS 473  
multinational alcohol corporations  
  373–4  
Murphy, T 62, 453  
mutual recognition 469  
  medical devices 26  
  medical qualifications 28  
  pharmaceuticals 159, 160, 163–5  
  prescriptions 246, 250  
mutual societies 444, 450  
Nanopoulos, E 86  
national courts  
  CJEU and 61, 62–70, 80  
  frequency of requests for  
   preliminary rulings 65–7  
  general principles of EU law 84  
  judicial review traditions 63–5  
  product liability 260  
  proportionality 67–9  
national parliaments 435  
NATO (North Atlantic Treaty  
  Organization) 322, 326  
Naurin, D 40  
Navarro-Michel, M 200  
Nazzini, R 267  
necessity 253, 262  
  alcohol control measures and  
  internal market 376–8  
Neergaard, U 277  
neoclassical economics 365  
neofunctionalism 71, 320, 345  
neoliberalism 67, 142–3  
Netherlands 29, 298, 309, 408  
  antibiotics 420  
  competition law 279–80, 286–7  
  ePrescriptions 252  
  health professional mobility 119  
  Patients' Rights Directive 49, 57  
  networks and agencies 43–4, 326–7,  
  346  
  health technology assessment  
  network 310  
  *see also individual agencies*  
neurodegenerative disorder 159, 198  
Neven, L 140  
new health technologies 197–221, 223,  
  344  
  arbitration 450  
  EU law and marketing of 211  
  advanced therapy medicinal  
  products 214–17, 220–21,  
  224–6  
  medical devices 217–19, 220–21  
  medicinal products 211–17,  
  220–21, 224–7  
  orphan medicinal products  
  212–14, 221  
  EU law and research on 200  
  funding 201–5, 220, 235  
  patent protection 205–10, 219–20,  
  235  
New Zealand 119  
Newdick, C 64, 181, 182, 183, 186, 190,  
  191  
Niemann, A 71, 320  
Nolan, A 298  
non-communicable diseases (NCDs)  
  369, 370–71, 394, 397, 409  
  *see also individual diseases; nutrition/  
  diet-related diseases*  
non-profit organisations 444  
Nordic countries 251  
norms and law 349–50, 368  
Norway 119, 360, 420  
Nowak, T 39

- Nowotny, H 139  
 nuclear threats 323  
 nudging 347–8, 350, 364, 367–8, 412  
 Nuremberg Trials 484  
 nurses  
   mobility *see* health professional  
   mobility  
   qualifications 117, 118, 127  
   working time 116, 117  
 nutrition and public health *see under*  
   food law  
 nutrition/diet-related diseases 398, 399,  
   405, 406, 408, 412–13, 422, 423,  
   424, 425  
   labelling of food 412  
   nutrition and health claims 415  
 Nwaka, S 459  
 Nys, H 51
- Obermaier, AJ 66  
 obesity 363, 398, 399, 405, 406–8, 409,  
   412–13, 422, 423, 424, 425  
   nutrition and health claims 415, 417  
   nutrition labelling 412  
 O’Connell, P 471  
 Odudu, O 267  
 van Oers, J 395  
 offshoring 245  
 Ognyanova, D 118, 129  
 Olsena, S 57  
 O’Neill, O 480, 484  
 Ong, A 154  
 Ono, T 112, 113, 116  
 open method of coordination (OMC)  
   31–2, 80  
 open science 148, 149, 151  
   digital agenda, biomedical research  
   and 145–7  
 ordinary legislative procedure 40, 42–3,  
   421, 432  
 organ trafficking 238, 240, 241  
 organ transplantation 227–30, 231,  
   237–8, 241, 455  
   buy and sell organs 239–40, 241,  
   471–2  
   consent 236  
   cross-border exchange 232, 233–4,  
   237  
   living donors 229, 231, 237, 240,  
   471–2
- O’Rourke, R 24  
 orphan medicinal products (OMPs) 25,  
   159, 161, 205, 212–14, 221  
 Oudshoorn, N 140  
 outsourcing 245  
 Owen, DG 173, 179, 183, 189
- Paina, L 112, 131  
 Pakistan 443  
 Palm, W 46  
 Panofsky, A 154  
 Paolucci, F 298  
 Parkinson’s disease 202, 208, 215  
 paroxetine 279  
 Parsons, C 36  
 participation  
   biomedical research law and policy  
   and citizen science *see separate*  
   *entry*  
 partnership model (state, private and  
   ‘third sector’ institutions) 118  
 Patel, KK 267  
 patents 25, 88, 95–7, 205–10, 219–20,  
   235, 344, 470  
   competition law and policy 274,  
   275–6  
 paternalism 412  
   libertarian 367  
 patient mobility 3, 438, 443–4, 445  
   case law 29, 30–31, 45–6, 49, 50–  
   51, 52–3, 55, 58–9, 91, 246,  
   344  
   Member States and CJEU 73–6  
   eHealth 245, 246  
 patients’ rights 3, 29, 32–3, 38, 39, 40,  
   45, 241, 299, 310, 474, 486  
   agenda-setting 45–7  
   dialogue between Member States  
   and CJEU 74–6  
   dignity 493  
   eHealth 245, 246, 249, 254  
   fundamental rights 98  
   how legislative output conditions  
   outcomes 55–9  
   political negotiations  
   Council 49–52  
   European Parliament 47–9  
   inter-institutional 52–5  
   trade 436–7  
 PatientsLikeMe 134

- Pavolini, E 117, 118, 126, 127, 132  
 Peeters, M 303  
 Pehlan, J 351  
 Pelkmans, SJ 26  
 Pennings, F 24  
 pensions 32  
 Pereira, C 124  
 Permanand, G 31, 44, 306  
 Pfizer 282–3  
 pharmaceuticals *see* medicinal products  
 pharmacists/pharmacies 33, 102–3, 105, 106, 273, 302, 307  
   ePharmacies and ePrescriptions 244, 245, 250–54  
   qualifications 117, 118  
 pharmacovigilance 162, 163, 169–70, 195, 216, 230  
 Phelan, DR 28  
 Pickering, A 139  
 Pieters, D 297  
 Pisani-Ferry, J 295  
 Plomer, A 87, 220  
 Pogge, TW 454  
 Poland 87, 235, 449  
   health professional mobility 119–22  
   Patients' Rights Directive 51, 52, 57  
 Pollack, MA 72, 392  
 Porter, D 137  
 Portugal 51, 295, 297–8, 360  
   health professional mobility 122, 123–5, 303  
 poverty reduction 460  
 Power, M 139  
 Prainsack, B 134, 142, 152  
 precautionary principle 316, 330, 331–3, 340, 345, 405, 475  
   trade and health 429–30, 465–6  
 Prechal, S 77  
 prescriptions *see* pharmacists/pharmacies  
 Price, D 238  
 Priest, GL 179  
 Princen, S 353  
 principal-agent model 71–2  
 privacy 85, 99, 202, 245, 445, 476  
   communicable diseases 315, 316  
   mobile health apps 255, 256  
 privatisation 1, 298, 311, 449, 490  
 procurement 284, 300, 431, 438, 445, 446  
   vaccines 334–5  
 product liability 172–4, 249  
   defect 173, 176–80, 260  
   development risks 180–82  
   interactions with regulation of medicinal products 182–96  
   mHealth 259–60  
   scope and structure 175–6  
 product placement 389, 390–91  
 professional organisations 130  
 proportionality 103–4, 105, 150, 202, 354, 370, 424  
   alcohol control measures and internal market 375–6, 377, 378, 394  
   communicable diseases 316  
   competition law 277, 278  
   eHealth 253, 262  
   national courts and CJEU 67–9  
 Prosser, WL 173  
 public health 23, 146, 150, 154  
   alcohol *see separate entry*  
   communicable diseases *see separate entry*  
   competence 7, 12, 19, 20, 21, 29–30, 37  
   alcohol 381  
   antibiotics in food-producing animals 422  
   communicable diseases 321  
   food law 399–400, 409, 412, 422, 423–5  
   global context 34  
   health values 479, 481–2, 486, 489–90  
   human materials 223, 227  
   new health technologies 199  
   tobacco 352, 354–8, 366, 481–2  
   trade policy 432–7, 451  
   distinguished from healthcare 21–2  
   ePublic health technologies 261–2  
   food law *see separate entry*  
   human materials 223, 227, 237, 240  
   investment protection 448–9  
   tobacco *see separate entry*  
 public health emergency of international concern (PHEIC) 338

- public-private partnerships 444, 446–7  
 Pugh, C 182, 192  
 Puska, P 383
- qualifications, professional 28, 115,  
 117, 118, 125, 127, 128, 130, 133,  
 303  
     eHealth 248  
 qualified majority vote 52, 352, 354,  
 434, 435  
 quarantine 316, 318, 337  
 Quinn, P 257
- Rabinow, P 142  
 ‘race to the bottom’ 164  
 ‘race to the top’ 468, 476  
 Radcliffe-Richards, J 239  
 rapid alert systems  
     cross-border health threats 262,  
     321–2  
     food law 323, 336  
     human materials 230–31  
 Rapp, R 154  
 rare diseases/conditions 33, 48, 53, 205,  
 215  
     orphan medicinal products (OMPs)  
     25, 159, 161, 205, 212–14, 221  
 rational decision-maker 365  
 Raychandhuri, K 261  
 Rebonato, R 412  
 referenda  
     France 29  
     Netherlands 29  
     United Kingdom 1, 11–13  
 registration of health professionals  
 248–9  
 registries, shared EU organ 238  
 registry of human pluripotent stem  
 cells lines 203  
 Regnstrom, J 306  
 regulation studies 136, 140, 142  
 Reis, MF 125  
 Renstrom, M 396  
 research *see* biomedical research law  
     and policy  
 Reynolds, L 464  
 Ribeiro, J 112, 124  
 Ribeyre, Paul 36  
 Rieder, C 79  
 rights-based approach 20, 29  
     *see also* fundamental rights; human  
     rights  
 risk assessment 166, 170, 180, 189, 192  
 communicable diseases 327, 328–31,  
 332, 336  
     data protection 258–9  
     food injurious to health 405  
 risk management 170  
     communicable diseases 326, 327–8,  
     330–31, 333, 334, 336  
     pharmaceuticals 170  
 Rittberger, B 322  
 Ritter, A 396  
 Robertson, A 409  
 Rocco, G 127, 128  
 Rodier, G 337, 341  
 Roemer, R 458  
 Romania 232, 297, 309  
     health professional mobility 119–22,  
     125, 127, 128–31  
     Patients’ Rights Directive 51, 52  
 Room, R 369, 395  
 Rose, N 137, 141, 154  
 Roux, T 471  
 Ruger, JP 454, 457  
 Ruggie, G 462  
 de Ruijter, A 19, 20, 21, 22, 29, 37, 40,  
 80, 94, 325, 333–4, 479, 483, 490,  
 491  
 Russia 119, 326  
 Rusu, CS 280  
 Rynning, E 242
- Saar, P 112  
 Sabel, CF 345  
 de Sadeleer, N 352  
 Salomon, ME 342  
 Samanta, N 466  
 San Miguel, L 252  
 Sandel, MJ 77–8, 454  
 SARS (severe acute respiratory  
 syndrome) 34, 322, 323, 458  
 Sauter, W 31, 32, 267, 269, 289  
 Sayers, D 98  
 Sbragia, A 432  
 Scharpf, F 20, 104, 137, 490  
 Scheingold, SA 320  
 school closures 334  
 Schütze, R 392  
 Schwebag, M 58

- science 7–9, 328–9, 330, 344, 492, 494, 495  
   antibiotics 419  
   citizen *see* biomedical research law and policy and citizen science  
   food: nutrition and health claims 414, 416  
   Science 2.0 142  
   scientific ‘fact’ 333  
   and technology studies (STS) 136, 139–42  
   *see also* biomedical research law and policy  
 scope of EU health law and policy 23, 35  
   1957–1992 23  
     food law 24–5  
     free movement of services 28–9  
     health and safety at work 28  
     medical devices 26–7  
     medical qualifications 28  
     pharmaceuticals 25–6  
     social security coordination 23–4  
     tobacco 27  
   1992–2007  
     agencies 31  
     integration context 29  
     open method of coordination and health 31–2  
     patient mobility case law 30–31  
     public health 29–30  
   2007 to present 32  
     European Semester 33–4  
     freedom of establishment 33  
     freedom of services: Patients’ Rights Directive 32–3  
     global context 34  
     third health programme and Europe 2020 33  
 Scott, C 137  
 Scott, J 465  
 self-employment 302  
 self-regulation 362, 384, 390, 396–7, 417–18  
 Selgelid, MJ 315  
 services of general economic interest (SGEI) 277–8, 283–6, 288–9  
 Shibuya, K 458  
 Sinclair, D 269  
 Singapore 438, 442  
 Singh, SN 245  
 single market *see* internal market/single market  
 Slovakia 449  
   health professional mobility 119–22, 125  
   Patients’ Rights Directive 51, 52  
 Slovenia 51, 420  
   health professional mobility 119–22  
 small and medium enterprises (SMEs) 205, 216  
 Smith, L 395  
 Smith, S 297  
 social inclusion 32  
 social open method of coordination 32  
 social security coordination 23–4, 36, 37, 45, 102, 309  
 socialisation 65  
 Socialists and Democrats (S&D) 48, 49  
 soft law 220, 241, 307, 310, 345–6, 454  
 solidarity 35, 79, 269, 278, 296, 308, 309, 475, 480, 482  
   constitutional setting of EU 491, 492, 494, 495  
   fundamental rights 486, 487–9  
   health professional mobility 131, 132, 133  
   human materials 239  
 Somek, A 61, 67, 73  
 sovereignty 35, 473  
 Spain 297, 420  
   health professional mobility 119, 122, 125  
   Patients’ Rights Directive 51–2, 57  
 Sperling, D 471, 472  
 sponsorship  
   alcohol 372, 389  
   tobacco 354–5  
 Stability and Growth Pact (SGP) 33, 292, 293, 492  
 Stamati, F 296, 298, 300  
 Stapleton, J 179, 180, 181, 260  
 State aid 31, 283–8  
 State-owned enterprises 438, 446–7  
 Steffen, M 21, 38  
 Steinberger, E 433  
 Steiner, HJ 474  
 Stokes, E 198, 200

- strategy
  - 2000 Lisbon 143–4
  - EU Alcohol Strategy 2006–2012
    - 383–6, 395–7
  - Europe 2020 30, 144, 146
  - health 106–7
- structural funds 491
- Stuckler, D 325
- Studlar, D 365, 476
- Stuyck, J 375
- subcontracting 245
- subsidiarity 30, 32, 35, 150, 354, 489
  - alcohol 370, 382, 391–4
  - Patients' Rights Directive 47
- subsidies and investment protection 449
- Sunstein, CR 471
- supremacy of EU law 84
- surveillance
  - health 261–2, 317, 321–2, 326, 346
- sustainable development 332
- Sweden 119, 172, 298, 420
  - Patients' Rights Directive 49, 51
- Sweet, AS 320
- Switzerland
  - health professional mobility 118, 119, 124
- Syrett, K 212
- Szajkowska, A 405
- Szyszczak, E 31, 285, 286
  
- Tallberg, J 40
- Taschner, HC 172, 182
- taxation 367
  - alcohol 372, 378, 380
  - fat tax 20
- Taylor, A 135, 458
- Taylor, JS 239
- Taylor, L 458
- telemedicine 248–50, 262–3
- teleshopping 389, 390
- Terry, NP 242
- Thaler, RH 412
- thalidomide 157, 172, 173
- third-country nationals (TCNs) 338
  - removal of person with serious illness 340
- Thomson, S 307
- Thorndike, AN 411
- Thym, D 100
  
- von Tigerstrom, B 457
- tissue and cells *see* human materials
- Titmuss, R. 238–9
- tobacco 18, 20, 27, 38, 59, 76, 90, 347–68, 380, 455
  - advertising 27, 76, 351, 352, 354–5, 366, 475, 492
- bilateral treaties
  - investment disputes 449
- class 350–51
- EU regulation of 354–8, 366, 475–6
- EU Tobacco Products Directive 353, 355–6, 358–61
  - tar, nicotine and carbon monoxide yields (TNCO) 359, 364–5
- genesis and development
  - of EU control 351–3
  - of global control 348–51
- low-tar cigarettes 364–5
- new frontiers of regulation 361–5
- nudging 347–8, 350, 364, 367–8
- packaging 347, 353, 359–61, 362–4, 366–7, 475
- plausible rival hypothesis 350
- trade law 438
- WHO 353, 361, 458
- Toebes, CA 454, 460, 482
- Torren-Edo, J 423
- tort
  - eHealth: applicable law 250
- tourism, health 437, 443–4, 445
- Tourney, C 152
- trade and development 459–60, 462–70
- trade and health 429–52
  - current trade negotiations 441
    - CETA 435, 438, 440, 441–3, 449, 450–51, 467
    - TiSA 434–5, 438, 441, 443–5, 467
    - TTIP 1, 345, 431, 434, 436, 438, 441, 443–4, 445–8, 449, 450, 452, 457, 468, 469
  - jurisdiction and competence 432–7
  - new-generation trade agreements and trade law
    - role of exclusions 439–41
    - policy space for health 437–9
- trade secrets 446, 448
- Trade in Services Agreement (TiSA) 434–5, 438, 441, 443–5, 467

- trade unions 130, 278  
 traditional herbal medicines 161  
 traffic regulations 103  
 training 115, 117, 125, 129–30, 304  
     communicable diseases 326  
     human materials 229  
     working time and doctors in 28  
 trans individuals 107  
 Trans-Pacific Partnership (TPP) 448, 450, 452, 467, 470  
 Transatlantic Trade and Investment Partnership (TTIP) 1, 345, 431, 434, 436, 438, 441, 443–4, 445–8, 449, 450, 452, 457, 468, 469  
 transitional countries 476  
 transparency 151, 262, 284, 285, 289, 329, 330, 331  
     pharmaceuticals 170–71, 192, 448  
     price 25–6  
     professional development 129  
 trade law 436, 446, 448  
     TiSA 445  
 trialogues 42, 49, 52  
 TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement 433, 464–5, 470, 472, 475  
 Tsouloufas, G 273  
 tuberculosis 34, 118, 459  
 Tulibacka, M 260  
 Turkey 443  
 Turner, BS 143  
 Tushnet, M 471  
 Tutton, R 238  
 ‘Uberisation’ of healthcare 263  
 Ukraine 466  
 Ulstein, A 373  
 unauthorised drugs  
     terminal illness 78  
 Ungureanu, M 129  
 United Kingdom 298  
     antibiotics 420  
     CFREU 87  
     competition law 278–9  
     data protection 99  
     ePrescriptions 252  
     health professional mobility 119, 124, 125  
     Human Fertilisation and Embryology Authority (HFEA) 69  
     human materials 229  
     human rights 64  
     judicial review 64  
     national courts and CJEU 64, 69  
     National Health Service (NHS) 279, 297  
     nurses 116, 117  
     working time 116, 117  
     new health technologies 204  
     nutrition labelling 411  
     organ transplantation  
         consent 236  
     Patients’ Rights Directive 49, 51  
     plasma 233  
     referendum (2016) 1, 11–13  
     thalidomide 172  
     tobacco 359–61  
     TPP 448, 450, 452, 467, 470  
     TTIP 1, 345, 431, 434, 436, 438, 441, 443–4, 445–8, 449, 450, 452, 457, 468, 469  
     UK Biobank 134  
 United Nations 446, 460  
     non-communicable diseases 370  
     Sustainable Development Goals 459  
 United States 119, 173, 178–9, 183, 189–90, 345, 401  
     Anthrax 318, 322  
     antibiotics 419  
     free trade agreements 431–2  
     health security 325  
     health tourism 437, 444  
     orphan medicines 212  
     TiSA 443  
     trade and health 465  
     trade law 429–30, 437, 444, 448  
 universality 308–9, 480, 482, 483  
     constitutional setting of EU 491, 492, 494  
     fundamental rights 486, 487–9  
 Uruguay 449  
 vaccines and immunisation 118, 316, 317, 333–6, 459  
     compulsory vaccination 335–6  
 values in EU health law and policy 9–11, 12–13, 479–83

- fundamental rights
  - health values and 483–5
  - health values in 485–90
- future research 494–5
- health law in EU constitutional setting 490–94
- Varju, M 208
- Varkevisser, M 281
- Vasev, N 56, 57
- Vayena, E 138, 141
- Vedder, H 276
- Viagra 253
- Vicarelli, G 126, 128
- Vogel, D 401, 429, 465
- Vogler, S 306, 308
- Vollaard, H 36, 38, 57
- Van Vooren, B 456
- Vos, E 21, 24, 28, 322, 417, 466
  
- Wagenaar, A 395
- Waldby, C 238
- Walker, G 140
- Wansink, B 417
- Warntjen, A 40
- Warren-Jones, A 198
- Watson, J 491
- Weatherill, S 76
- Web 2.0-enabled Science 2.0 and Med 2.0 platforms 142
- Weiler, JHH 63, 65, 67
- Westin, J 274
- Whish, R 270
- Whittaker, S 175, 181, 186, 188
- Wiggers, MPM 279
- Wilkinson, S 239
- Wilsdon, J 135
- Wismar, M 112, 113, 126, 129
- Wolf, JA 259
- women
  - carers 117
  - nurses 117
- Woolgar, S 140
  
- working time 28, 37, 39, 59, 116, 117, 132
- World Bank 338–9, 455, 459, 473
- World Health Assembly 197, 369
- World Health Organisation (WHO) 12, 34, 197, 240, 243, 446, 452, 457–8, 459, 475
  - alcohol 370–71, 374, 379, 380
  - antimicrobial resistance 419
  - communicable diseases 320, 326, 335, 338–9
  - definition of health 404
  - ePharmacies 252
  - non-communicable diseases 371, 409
  - obesity 406–7
  - recruitment of health personnel 122–3, 131
  - tobacco 353, 361, 458
- World Trade Organisation (WTO) 329, 429, 433, 444, 446, 455, 457, 475
  - development and trade 462, 463–7, 469, 470
  - dispute settlement 429–31, 475
  - liberalism, modified or embedded 462, 465, 469, 470
- Wyatt, D 366
- Wynne, BE 142
- Wyss, L 187
  
- Yeung, K 140
- Young, AR 466
- Young, KG 64
- Young, R 112
  
- Zahariadis, N 318
- Zamparutti, T 397
- Zeitlin, J 32
- Ziegler, DW 449
- Zika virus 316, 338, 344
- Zimmer, D 267
- Zuniga, JM 471